Additionally, our findings are consistent with prior reports on the associations between regional tau retention and specific cognitive domains [12] and further highlight the feasibility of using brief and robust cognitive measures as indicators of potential AD-related pathological changes addressing the shortcomings of cost- and time-prohibitive neuropsychological batteries. This evidence concerns the gene MAPT and Alzheimer disease.